Business Wire (Thu, 12-Feb 7:30 AM ET)
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing
Globe Newswire (Tue, 10-Feb 4:05 PM ET)
Globe Newswire (Mon, 12-Jan 4:05 PM ET)
Globe Newswire (Thu, 18-Dec 7:00 AM ET)
Halper Sadeh LLC Encourages AVDL, CMA, KVUE Shareholders to Contact the Firm to Discuss Their Rights
Globe Newswire (Sun, 14-Dec 1:18 PM ET)
PRNewswire (Fri, 12-Dec 4:38 PM ET)
Market Chameleon (Fri, 14-Nov 5:35 AM ET)
Avadel Faces Higher Bid: Lundbeck’s $23.00 Offer Challenges Existing Alkermes Agreement
Market Chameleon (Fri, 14-Nov 2:06 AM ET)
Market Chameleon (Wed, 22-Oct 3:57 AM ET)
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Avadel Pharmaceuticals PLC - Ordinary Share trades on the NASDAQ stock market under the symbol AVDL.
As of March 6, 2026, AVDL stock price was flat at $21.64 with million shares trading.
AVDL has a beta of 1.19, meaning it tends to be more sensitive to market movements. AVDL has a correlation of 0.17 to the broad based SPY ETF.
AVDL has a market cap of $2.12 billion. This is considered a Mid Cap stock.
Last quarter Avadel Pharmaceuticals PLC - Ordinary Share reported $77 million in Revenue and $.00 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.05.
In the last 3 years, AVDL traded as high as $23.57 and as low as $6.38.
The top ETF exchange traded funds that AVDL belongs to (by Net Assets): VTI, VXF, VTWO, VHT, VTWG.
AVDL has outperformed the market in the last year with a price return of +174.6% while the SPY ETF gained +18.7%. AVDL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +1.4% and 0.0%, respectively, while the SPY returned -1.7% and -2.5%, respectively.
AVDL support price is $21.61 and resistance is $21.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVDL shares will trade within this expected range on the day.
